Safety outcomes of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and other risk factors for cardiovascular disease: a systematic review and meta-analysis

Sodium-glucose cotransporter-2 inhibitors (SGLT2-Is) have emerged as standard therapy for heart failure. We aim to assess the safety of SGLT2-Is in patients with a high risk of cardiovascular disease. AREAS COVERED: An electronic database search was conducted for randomized control trials comparing...

Descripción completa

Detalles Bibliográficos
Autores principales: Deshpande, Radhika, Patel, Raj, Regmi, Manjari R., Salih, Mohsin, Kropp, Robert, Al-Bast, Basma, Sheikh, Muhammad A., Sagalov, Andrew, Kulkarni, Abhishek, Siddique, Momin, Hegde, Shruti, Bhattarai, Mukul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171571/
https://www.ncbi.nlm.nih.gov/pubmed/37180737
http://dx.doi.org/10.1097/XCE.0000000000000284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171571/
https://www.ncbi.nlm.nih.gov/pubmed/37180737
http://dx.doi.org/10.1097/XCE.0000000000000284

Ejemplares similares